In the last trading session, 1.6 million shares of the Taysha Gene Therapies Inc (NASDAQ:TSHA) were traded, and its beta was 0.88. Most recently the company’s share price was $1.63, and it changed around $0.01 or 0.62% from the last close, which brings the market valuation of the company to $334.15M. TSHA currently trades at a discount to its 52-week high of $4.32, offering almost -165.03% off that amount. The share price’s 52-week low was $1.19, which indicates that the current value has risen by an impressive 26.99% since then.
Taysha Gene Therapies Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.09. If we narrow it down even further, the data shows that 0 out of 11 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 0 recommended TSHA as a Hold, whereas 7 deemed it a Buy, and 0 rated it as Underweight. Taysha Gene Therapies Inc is expected to report earnings per share of -0.1 for the current quarter.
Taysha Gene Therapies Inc (NASDAQ:TSHA) trade information
Instantly TSHA has showed a green trend with a performance of 0.62% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.8850 on recent trading dayincreased the stock’s daily price by 13.53%. The company’s shares are currently down -5.78% year-to-date, but still down -4.12% over the last five days. On the other hand, Taysha Gene Therapies Inc (NASDAQ:TSHA) is 8.67% up in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $8.5, which translates to bulls needing to increase their stock price by 80.82% from its current value. Analyst projections state that TSHA is forecast to be at a low of $5 and a high of $44.
Taysha Gene Therapies Inc (TSHA) estimates and forecasts
The year-over-year growth rate is expected to be -19.50%, down from the previous year.
Consensus estimates provided by 10 financial analysts predict the company will bring in an average of 1.71M in revenue for the current quarter. 10 analysts expect Taysha Gene Therapies Inc to make 1.99M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 3.41M and 1.11M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -49.95%. Forecasts for the next quarter put sales growth at 79.17%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -63.99%. Taysha Gene Therapies Inc earnings are expected to increase by -0.62% in 2025, but the outlook is negative -0.24% per year for the next five years.
TSHA Dividends
Taysha Gene Therapies Inc’s next quarterly earnings report is expected to be released in April.
RTW INVESTMENTS, LP, with 8.075% or 18.8 million shares worth $42.11 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 4.72 shares worth $7.69 million, making up 2.30% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 4.46 shares worth around $7.26 million, which represents about 2.17% of the total shares outstanding.
